Inhibitory effect of withaferin A on Helicobacter pylori-induced IL-8 production and NF-κB activation in gastric epithelial cells
Author(s) -
Green Kim,
TaeHyoun Kim,
MinJung Kang,
Jina Choi,
Dayoung Pack,
IK-RAE LEE,
MIN-GYU KIM,
SangSeop Han,
Bo-Yeon Kim,
SangMuk Oh,
KyungBok Lee,
DongJae Kim,
JONG-HWAN PARK
Publication year - 2015
Publication title -
molecular medicine reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.727
H-Index - 56
eISSN - 1791-3004
pISSN - 1791-2997
DOI - 10.3892/mmr.2015.4602
Subject(s) - withaferin a , helicobacter pylori , inflammation , western blot , interleukin 8 , vascular endothelial growth factor , biology , withania somnifera , microbiology and biotechnology , pharmacology , cancer research , immunology , medicine , biochemistry , pathology , vegf receptors , alternative medicine , gene , genetics
Withaferin A (WA), a withanolide purified from Withania somnifera, has been known to exert anti-inflammatory effects. The present study sought to determine the effects of WA on Helicobacter (H.) pylori-mediated inflammation in the AGS gastric epithelial cell line. Cellular production of interleukin (IL)-8 and vascular endothelial growth factor (VEGF) was measured by ELISA. Western blot analysis was performed to determine the activation of nuclear factor (NF)-κB and mitogen-activated protein kinases (MAPKs) as well as hypoxia-inducible factor 1α stabilization. Bacterial growth was also examined by measuring the optical density. Pre-treatment or co-treatment with WA efficiently reduced IL-8 production by AGS cells in response to H. pylori infection. H. pylori-induced activation of NF-κB, but not MAPKs, was also inhibited by pre-treatment of WA in the cells. However, WA did not affect VEGF production and HIF-1α stabilization induced by H. pylori in AGS cells. In addition, WA did not influence the growth of H. pylori, suggesting that the anti-inflammatory effect of WA was not due to any bactericidal effect. These findings indicate that WA is a potential preventive or therapeutic agent for H. pylori-mediated gastric inflammation.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom